22 February 2024
22 February 2024 07:00 GMT AstraZeneca prices a $5bn bond offering AstraZeneca PLC (“AstraZeneca”) announces that its wholly owned subsidiary AstraZeneca Finance LLC, priced a four…
Herald Investment Trust plc Annual Financial Report For the year ended 31 December 2023 Results and dividend The net asset value (‘NAV’) of the…
Underlying operating profit of £1.6bn and underlying margin of 10.3%, reflecting the impact of our strategic initiatives, with commercial optimisation and cost efficiency benefits…
22 February 2024 LLOYDS BANKING GROUP PLC – ANNUAL REPORT AND ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2023 In accordance with Listing Rule…
21 February 2024
Nestlé reports full-year results for 2023 FEB 22, 2024 Back to Press releases Vevey, Switzerland [Ad hoc announcement pursuant to Art. 53 LR] Follow…
21 February 2024 07:00 GMT Filing of Annual Report on Form 20-F with the US Securities and Exchange Commission AstraZeneca PLC (the Company) announced today that,…
21 February 2024 Production growth of 3% from focused investment in the health of our business; underlying EBITDA of $23.9 billion and full year ordinary…
LATITUDE phase III interim trial data indicates ViiV Healthcare’s long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) has superior efficacy compared to daily therapy in individuals…